BioTuesdays
Humanigen Logo
Markets

Cantor cuts Humanigen to neutral; PT to $2

Cantor Fitzgerald downgraded Humanigen (NASDAQ:HGEN) to “neutral” from “overweight” and slashed its price target to $2 from $30 after a failed COVID-19 study. The stock closed at $2.99 on July 12. The National Institute...

July 13, 2022
Atara logo
Markets

Stifel cuts Atara Biotherapeutics to hold; PT to $5

Stifel downgraded Atara Biotherapeutics (NASDAQ:ATRA) to “hold” from “buy” and lowered its price target to $5 from $16, following the company’s interim Phase 2 analysis with ATA188 for the treatment of multiple...

July 13, 2022
OpGen Logo
Markets

AGP cuts OpGen to neutral; PT to 67 cents

Alliance Global Partners downgraded OpGen (NASDAQ:OPGN) to “neutral” and lowered its price target to 67 cents, citing the company’s cash needs. The stock closed at 61 cents on July 11. “We view the company’s...

July 12, 2022
T2 Biosystems Logo
Markets

AGP cuts T2 Biosystems to neural; PT to 14 cents

Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” and reduced its price target to 14 cents from 65 cents, citing a fiscal second quarter preliminary revenue miss. The stock was...

July 7, 2022
Point Biopharma Logo
Markets

WB starts POINT Biopharma at outperform

William Blair initiated coverage of POINT Biopharma Global (NASDAQ:PNT) with an “outperform” rating based on a view that the Street is “underestimating the clinical and commercial potential of the company’s...

July 6, 2022
Aileron Therapeutics Logo
Markets

HCW cuts Aileron Therapeutics PT to $1 from $2

H.C. Wainwright reduced its price target for Aileron Therapeutics (NASDAQ:ALRN) to $1 from $2, but maintained its “buy” rating, after the company reported “underwhelming” interim data from a Phase 1 study in non-small...

June 30, 2022
Theseus Logo
Markets

HCW starts Theseus Pharma at buy; PT $22

H.C. Wainwright launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and price target of $22. The stock closed at $5.20 on June 29. “We believe pan-inhibition could be the key to success in...

June 30, 2022
Neximmune Logo
Markets

Cantor assumes coverage of Neximmune at OW; PT $4

Cantor Fitzgerald analyst Prakhar Agrawal assumed coverage of Neximmune (NASDAQ:NEXI) with an “overweight” rating and price target of $4. The stock closed at $1.61 on June 29. Neximmune is developing a novel T-cell...

June 30, 2022
Acumen Pharmaceuticals Logo
Markets

HCW starts Acumen Pharma at buy; PT $15

H.C. Wainwright initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $15 price target. The stock closed at $4.88 on June 29. Acumen is a clinical-stage biopharmaceutical company developing...

June 30, 2022
Aileron Therapeutics Logo
Markets

WB cuts Aileron Therapeutics to market perform

William Blair downgraded Aileron Therapeutics (NASDAQ:ALRN) to “market perform” after the company released interim data from a Phase trial of ALRN-6924 as a chemoprotectant in patients with non-small cell lung cancer...

June 29, 2022
Akoya Logo
Markets

BTIG starts Akoya Biosciences at buy; PT $16

BTIG launched coverage of Akoya Biosciences (NASDAQ:AKYA) with a “buy” rating and $16 price target. The stock closed at $9.29 on June 21. Akoya is a rapidly growing life sciences technology company that offers a...

June 22, 2022
Celularity
Markets

HCW starts Celularity at buy; PT $15

H.C. Wainwright initiated coverage of Celularity (NASDAQ:CELU) with a “buy” rating and $15 price target. The stock closed at $3.78 on June 21. Celularity is a clinical-stage biopharmaceutical company focused on...

June 22, 2022
Kymera Logo
Markets

Brookline ups Kymera Therapeutics PT to $93 from $80

Brookline Capital Markets raised its price target for Kymera Therapeutics (NASDAQ:KYMR) to $93 from $80 after the company dosed the first patients in separate Phase 1 studies for its KT-333 and KT-413 product candidates...

June 21, 2022
Medivir AB Logo
Markets

Maxim starts Medivir at buy; PT $3

Maxim Group initiated coverage of Sweden-based Medivir AB (OMX:MVIR-B) with a “buy” rating and $3 price target. The stock closed at 77 cents on June 16. Medivir is developing MIV-818 (fostrox), a prodrug of the...

June 17, 2022
Markets

Maxim starts Femasys at buy; PT $5

Maxim Group launched coverage of Femasys (NASDAQ:FEMY) with a “buy” rating and $5 price target. The stock closed at $1.30 on June 16. Femasys is developing treatments to address the two extremes of the women’s...

June 17, 2022
ABVC BioPharma Logo
Markets

Maxim starts ABVC BioPharma at buy; PT $3

Maxim Group initiated coverage of ABVC BioPharma (NASDAQ:ABVC) with a “buy” rating and price target of $3. The stock closed at 96 cents on June 16. ABVC is developing assets in ophthalmology, mental health, and oncology...

June 17, 2022
Virpax Pharmaceuticals
Markets

Maxim starts Virpax at buy; PT $4

Maxim Group initiated coverage of Virpax Pharmaceuticals (NASDAQ:VRPX) with a “buy” rating and price target of $4. The stock closed at $1.55 on June 8. Virpax is a diversified pre-clinical stage company developing non...

June 9, 2022
Selecta Biosciences
Markets

SVB starts Selecta Biosciences at OP; PT $7

SVB Securities initiated coverage of Selecta Biosciences (NASDAQ:SELB) with an “outperform” rating and $7 price target. The stock closed at 88 cents on June 3. Selecta is a clinical-stage biotech company advancing its...

June 6, 2022
Markets

Cantor starts ObsEva at OW; PT $6

Cantor Fitzgerald launched coverage of ObsEva (NASDAQ:OBSV) with an “overweight” rating and a 12-month price target of $6. The stock closed at $1.96 on June 2. ObsEva is building a portfolio of best-in-class assets...

June 3, 2022